The FDA medical panel voted 16 to 9 that current data doesn’t prove that Aleve is safer to take. The vote came after several studies claimed that taking naproxen, which is sold as Aleve, is less likely to result in cardiac problems. The FDA panel agreed that Aleve could poetentially be safer, but that there wasn’t enough data to back up the claim, reports USA Today.
“To say naproxen is safer, I think that would be a slippery slope for FDA and consumers,” Victoria Richards, a professor of medicine at the Quinnipiac University School of Medicine in North Haven, Conn., told USA Today.
One FDA panelist that supported the claim that Aleve is safer than other non-steroidal anti-inflammatory drugs (NSAID) said that the data wasn’t conclusive, but that the panel had the “duty to inform the public.” Another member of the FDA panel said that the data was enough to convince him to switch the NSAIDs he takes to naproxen, ABC News notes.